# Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

> **NCT05557942** · PHASE3 · TERMINATED · sponsor: **Aerovate Therapeutics** · enrollment: 186 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** AV-101

## Key facts

- **NCT ID:** NCT05557942
- **Lead sponsor:** Aerovate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-02
- **Primary completion:** 2024-08-08
- **Final completion:** 2024-08-08
- **Target enrollment:** 186 (ACTUAL)
- **Why stopped:** Results from the parent study (IMPAHCT) demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05557942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05557942, "Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05557942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*